Novo Nordisk A/S (NYSE:NVO) Upgraded at UBS Group

UBS Group upgraded shares of Novo Nordisk A/S (NYSE:NVO) from a sell rating to a buy rating in a research note released on Wednesday morning, Marketbeat reports.

Several other analysts have also weighed in on NVO. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. BMO Capital Markets decreased their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Finally, StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $140.20.

Novo Nordisk A/S Stock Up 0.9 %

Shares of Novo Nordisk A/S stock opened at $86.41 on Wednesday. The stock’s 50-day moving average is $100.35 and its 200 day moving average is $119.40. Novo Nordisk A/S has a one year low of $81.50 and a one year high of $148.15. The firm has a market cap of $387.77 billion, a price-to-earnings ratio of 27.96, a PEG ratio of 1.37 and a beta of 0.45. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75.

Hedge Funds Weigh In On Novo Nordisk A/S

Hedge funds have recently bought and sold shares of the company. Strategic Investment Solutions Inc. IL purchased a new stake in shares of Novo Nordisk A/S during the 2nd quarter valued at $25,000. Abound Wealth Management lifted its holdings in shares of Novo Nordisk A/S by 257.4% in the second quarter. Abound Wealth Management now owns 218 shares of the company’s stock worth $31,000 after buying an additional 157 shares in the last quarter. Daiwa Securities Group Inc. bought a new position in shares of Novo Nordisk A/S in the third quarter worth $28,000. Capital Performance Advisors LLP bought a new position in Novo Nordisk A/S in the 3rd quarter worth about $42,000. Finally, Carolina Wealth Advisors LLC bought a new position in shares of Novo Nordisk A/S in the third quarter worth approximately $48,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.